Evidence map›Paper›PMID 35500285›Full record

ArticleBlood advances2023

CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia.

Astrid Wintering, Kenichi Ishiyama, Stanley Tamaki, Courtney Tamaki, Joshua Fandel, Lingyun Ji, Brent L Wood, Nirali N Shah, Constance M Yuan, Maureen M O'Brien and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Astrid WinteringDepartment of Pediatrics, Benioff Children's Hospital, and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-3731-6928
Kenichi IshiyamaDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-9377-2098
Stanley TamakiParnassus Flow Cytometry Core, University of California San Francisco, San Francisco, CA.
Courtney TamakiParnassus Flow Cytometry Core, University of California San Francisco, San Francisco, CA.
Joshua FandelDepartment of Pediatrics, Benioff Children's Hospital, and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
Lingyun JiDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Brent L WoodDepartment of Pathology, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0001-7414-3969
Nirali N ShahCenter for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-8474-9080
Constance M YuanCenter for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-2601-3665
Maureen M O'BrienDivision of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0002-9054-4321
Mignon L LohBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, University of Washington, Seattle, WA.
Ernesto Diaz-FloresDepartment of Pediatrics, Benioff Children's Hospital, and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-2406-4597
University of California, San Francisco · USNational Cancer Institute · USUniversity of Southern California · USCincinnati Children's Hospital Medical Center · USSeattle Children's Hospital · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Immunotherapeutic approaches to treat pediatric hematologic malignanciesZIABC011823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$6.1M
NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, Monoclonal, HumanizedHumansInotuzumab OzogamicinAntibodies, Monoclonal, HumanizedInotuzumab Ozogamicin

Identifiers

PMID35500285
PMCPMC9840233
OpenAlexW4225329131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.